

Rheumatoid arthritis (update) Committee meeting

Date: 19/12/2016

Location: Boardroom, NGC, 180 Great Portland Street, London, W1W 5QZ

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:		
Stephen Ward (SW, Chair)		(Present for notes 4–6)
Ann Bevan (ABe)		(Present for notes 1–6)
Ailsa Bosworth (ABo)		(Present for notes 1–6)
Vicky Chamberlain (VC)		(Present for notes 1–6)
Jennie Jones (JJ)		(Present for notes 1–6)
Bruce Kirkham (BK)		(Present for notes 1–6)
Hilary McKee (HMK)		(Present for notes 1–6)
Frank McKenna (FMK, Chaired items 1-3)		(Present for notes 1–6)
Anupama Nandagudi (AN)		(Present for notes 1–6)
Louise Warburton (LW)		(Present for notes 1–6)

In attendance:		
Anne-Louise Clayton (AC)	Editor, NICE	(Present for notes 1–5b)
Caroline Keir (CK)	Guideline Commissioning Manager, NICE	(Present for notes 1–6)
Jane Lynn (JL)	Business Analyst, NICE	(Present for notes 1–5c)
Alex Allen (AA)	Senior Research Fellow, NGC	(Present for notes 1–6)
Joanna Ashe (JA)	Senior Information Scientist, NGC	(Present for notes 5a, 5c–5d)
Serena Carville (SC)	Guideline Lead/Associate Director, NGC	(Present for notes 1–6)
Meredith Faust (MF)	Document Editor/Process Assistant, NGC	(Present for notes 1–6)
Lefteris Floros (LF)	Health Economist, NGC	(Present for notes 1–6)
Martin Harker (MH)	Senior Health	(Present for notes 1–5c)

	Economist, NGC	
Ben Pordes (BPo)	Acting Senior Project Manager, NGC	(Present for notes 1–6)
Jacqui Real (JR)	Senior Research Fellow, NGC	(Present for notes 1–6)

Apologies:

Benjamin Parker (BP)	Consultant Rheumatologist and Honorary Professor of Translational Rheumatology
Heidi Siddle (HS)	Principal Podiatrist and Associate Professor

1. Welcome and objectives for the meeting

FMK welcomed the committee members and attendees to the third meeting on rheumatoid arthritis. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Committee were informed that apologies had been received. These are noted above.

The objectives of the meeting were outlined, which included the health economic plan, analgesics review, and draft protocols.

2. Confirmation of matter under discussion, and declarations of interest

FMK confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was the health economic plan, analgesics review, and draft protocols.

FMK asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Bruce Kirkham	Consultant Rheumatologist, Guy's & St Thomas' NHS Foundation Trust	Attendance and participation presenting to the PSANO meeting Oslo (Psoriatic arthritis) 20	Personal, financial, non-specific	Declare and participate

		January 2017 supported by Novartis Norway = airfare and honorarium.		
Anupama Nandagudi	Consultant Rheumatologist, Basildon and Thurrock University Hospital NHS Trust	Honorarium for attending a meeting sponsored by Lilly. £250 honoraria received.	Personal, financial, non-specific	Declare and participate
		IMS Health – market research regarding drug rep interactions. £75.	Personal, financial, non-specific	Declare and participate

FMK and a senior member of the Developer’s team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

FMK asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.

4. Presentations

The Chair introduced Anne-Louise Clayton, Editor at NICE, who gave a presentation on writing recommendations.

AC took questions from the group.

5. Questions and discussion

- a) The Committee discussed the treat-to-target protocol question of ‘In adults with rheumatoid arthritis, what is the clinical and cost effectiveness of a treat-to-target management strategy, compared with usual care?’ and were given the opportunity to refine the protocol.
- b) The Committee discussed the health economic plan, specifically the question: ‘Is the management of people with poor prognosis rheumatoid arthritis different from

the rest of the population with rheumatoid arthritis?’ and were given the opportunity to ask questions and finalise the areas of priority for economic modelling.

- c) The Committee discussed the prognosis protocol question of ‘In adults with rheumatoid arthritis, which features help to identify the prognosis of the disease (disease progression)?’ and were given the opportunity to refine the protocol.
- d) The Committee discussed the early DMARD introduction protocol question of ‘In adults with [mild] rheumatoid arthritis, what is the clinical and cost effectiveness of early introduction of conventional DMARDs?’ and were given the opportunity to refine the protocol.

6. Any other business

The Chair introduced Ben Pordes, Acting Senior Project Manager at the NGC, who gave a demonstration on SharePoint.

BPo took questions from the group.

Date of next meeting: 30/01/2017

Location of next meeting: Boardroom, National Guideline Centre, 180 Great Portland Street, London, W1W 5QZ